|
The
following potentially dilutive securities were excluded from the calculation of diluted net loss per share because their effect would
have been antidilutive:
Schedule
of Anti-dilutive Securities
| |
|
2026 |
|
|
2025 |
|
| |
|
Six months ended June 30,
|
|
| |
|
2026 |
|
|
2025 |
|
| Stock options |
|
|
1,076,312 |
|
|
|
24,012 |
|
| Warrants |
|
|
17,687 |
|
|
|
19,457 |
|
| Common shares issuable upon conversion of Series F Preferred Stock |
|
|
249,624 |
|
|
|
- |
|
| Common shares issuable upon conversion of warrants attached to Series H Preferred Stock |
|
|
23,925,000 |
|
|
|
- |
|
| Common shares issuable upon conversion of Series H Preferred Stock |
|
|
15,389,322 |
|
|
|
- |
|
| Total |
|
|
40,657,945 |
|
|
|
43,469 |
|
|